Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India

Author:

Krishna Sri,Mishra Sweta,Tiwari Prakash,Vishwakarma Anup K.,Khandai Sushrikanta,Shrivastava Suyesh,Verma Anil K.,Tiwari Shashikant,Barman Hari,Jhariya Surendra,Tiwari Pradeep,Tidgam Anup S.,Varun Brij M.,Singh Sunil,Yerane Naresh,Tembhurne Chintaman R.,Mandavi Prem L.,Tekam Shyam S.,Malik Manas,Behera Kali P.,Jayswar Himanshu,Sonwani Khemraj,Diggikar Mukund S.,Pradhan Madan M.,Khasotiya Sher S.,Kumar Avdhesh,Dhingra Neeraj,Bustos Maria Dorina G.,Christophel Eva-Maria,Ringwald Pascal,Kumari Roop,Shukla Man M.,Singh Neeru,Das Aparup,Bharti Praveen K.ORCID

Abstract

Abstract Background Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme. Artemether-lumefantrine (AL) is the first-line treatment of uncomplicated Plasmodium falciparum in north eastern states of India since 2013 after confirming the resistance against sulfadoxine-pyrimethamine. In the present study, therapeutic efficacy of artemether-lumefantrine and k13 polymorphism was assessed in uncomplicated P. falciparum malaria. Methods This study was conducted at four community health centres located in Koraput district of Odisha, Bastar district of Chhattisgarh, Balaghat district of Madhya Pradesh and Gondia district of Maharashtra state. Patients with uncomplicated P. falciparum malaria were administered with fixed dose combination (6 doses) of artemether-lumefantrine for 3 days and clinical and parasitological response was recorded up to 28 days as per World Health Organization protocol. Nucleotide sequencing of msp1 and msp2 gene was performed to differentiate between recrudescence and reinfection. Amplification and sequencing of k13 propeller gene region covering codon 450–680 was also carried out to identify the polymorphism. Results A total 376 malaria patients who fulfilled the enrolment criteria as well as consented for the study were enrolled. Total 356 patients were followed up successfully up to 28 days. Overall, the adequate clinical and parasitological response was 98.9% and 99.4% with and without PCR correction respectively. No case of early treatment failure was observed. However, four cases (1.1%) of late parasitological failure were found from the Bastar district of Chhattisgarh. Genotyping of msp1 and msp2 confirmed 2 cases each of recrudescence and reinfection, respectively. Mutation analysis of k13 propeller gene showed one non-synonymous mutation Q613H in one isolate from Bastar. Conclusions The study results showed that artemether-lumefantrine is highly effective in the treatment of uncomplicated P. falciparum malaria among all age groups. No functional mutation in k13 was found in the study area. The data from this study will be helpful in implementation of artemether-lumefantrine in case of treatment failure by artesunate plus sulfadoxine-pyrimethamine.

Funder

WHO country office, India.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Parasitology

Reference29 articles.

1. WHO. World Malaria Report 2018. Geneva, World Health Organization, 2018. http://www.who.int/malaria/publications/world-malaria-report-2018/report/en/ Accessed 18 Oct 2019

2. National vector borne disease control programme (NVBDCP) http://nvbdcp.gov.in/Doc/malaria-situation.pdf. Accessed 18 Oct 2019

3. Kumar A, Valecha N, Jain T, Dash AP. Burden of malaria in India: retrospective and prospective view. Am J Trop Med Hyg. 2007;77(Suppl 6):69–78.

4. Sehgal PN, Sharma MI, Sharma SL, Gogai S. Resistance to chloroquine in falciparum malaria in Assam State. India J Commun Dis. 1973;5:175–80.

5. Farooq U, Mahajan RC. Drug resistance in malaria. J Vector Borne Dis. 2004;41:45–53.

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3